Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials

Repeat antenatal HIV testing in the third trimester: a study of feasibility and maternal uptake rates

(2013) B Williams et al.   HIV MEDICINE

Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial

(2011)   LANCET INFECTIOUS DISEASES

Antiretroviral Regimens in Pregnancy and Breast-Feeding in Botswana

(2010) R.L. Shapiro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients

(2009) Jean-François Delfraissy et al.   AIDS

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

(2009) Roberto Ortiz et al.   AIDS

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

(2009) Kimberly Y Smith et al.   AIDS

Lopinavir/Ritonavir in Pregnancy

(2009) Susan S Roberts et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

(2008) Jean-Michel Molina et al.   LANCET

Efficacy and safety of tenofovir/emtricitabine compared to abacavir/lamivudine in HIV-1 infected patients in clinical setting. The TEAL study

(2008) KJ Eccleston et al.   Journal of the International AIDS Society

HIV treatment decision making: high rate of revised treatment choices based upon different genotypic interpretation systems

(2008) E Wolf et al.   Journal of the International AIDS Society